Related Experiment Video

Updated: Jul 6, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

The future of obesity: new drugs versus lifestyle interventions

André J Scheen

    Expert Opinion on Investigational Drugs
    |March 7, 2008
    PubMed
    Abstract

    Insights

    Lifestyle interventions are key for obesity management, but often fall short. New anti-obesity medications can be valuable additions to improve weight loss and health outcomes when combined with lifestyle changes.

    Area of Science:

    • Endocrinology
    • Metabolic Diseases
    • Pharmacology

    Background:

    • Obesity presents significant health challenges and reduces quality of life, with management remaining complex.
    • Effective strategies are crucial for addressing the growing global obesity epidemic.

    Discussion:

    • This analysis critically evaluates the long-term efficacy of lifestyle interventions (diet, exercise) and anti-obesity medications (orlistat, sibutramine, rimonabant).
    • Evidence suggests that while lifestyle interventions are foundational, adherence and long-term success are often limited.
    • Pharmacological agents show potential as adjuncts to enhance weight loss and maintenance.

    Key Insights:

    • Lifestyle interventions are the primary treatment for obesity, but patient adherence and sustained results can be challenging.
    • Anti-obesity drugs can serve as beneficial add-ons, improving weight management and health outcomes in suitable patients.
    • Combining drug therapy with lifestyle interventions offers a synergistic approach to tackling obesity.

    Outlook:

    • Future research should focus on optimizing combination therapies for sustained obesity management.
    • Personalized treatment approaches considering individual patient responses to pharmacotherapy are warranted.
    • Continued evaluation of long-term safety and efficacy of anti-obesity agents is essential.

    More Related Videos

    An Acupoint Catgut-embedding Therapy for Treating Obesity04:50

    An Acupoint Catgut-embedding Therapy for Treating Obesity

    Published on: April 4, 2025

    Control of Eating Behavior Using a Novel Feedback System04:48

    Control of Eating Behavior Using a Novel Feedback System

    Published on: May 8, 2018

    Related Concept Videos

    Drug Dosing: Obese Patients01:21

    Drug Dosing: Obese Patients

    In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
    Obesity01:24

    Obesity

    The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
    Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

    Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

    Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
    Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

    Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

    Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
    Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

    Hypertension IV: Drug Therapy and Lifestyle Modifications

    Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
    Atherosclerosis III: Management01:26

    Atherosclerosis III: Management

    Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...